New Haven, Conn.-based Yale New Haven Health has become the first health system in the state to offer Flyrcado, a new PET imaging agent approved by the FDA to help clinicians detect coronary artery disease.
The tracer enhances the accuracy of cardiac PET imaging by identifying reduced blood flow and enabling clearer visualization of coronary artery blockages. It is the first new cardiac perfusion agent approved by the FDA in nearly three decades, according to a Jan. 12 system news release shared with Becker’s.
The technology enables exercise-based PET scans for the first time, enabling clinicians to assess patients during physical activity rather than relying solely on medication-induced stress.
The agent, which also delivers higher-quality images and improved sensitivity over older non-PET tracers, will be expanded to the system’s other hospitals, according to the release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
